Precipio, Inc. (PRPO)
NCM · Healthcare · Diagnostics & Research
$27.32
+1.52%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$48.9M
Shares Outstanding
1.8M
P/S (TTM)
1.8x
Exchange
NCM
Currency
USD
About Precipio, Inc.
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 6.8M | 6.7M | 6.7M | 7.0M |
| Gross Profit | 3.0M | 3.1M | 2.7M | 3.1M |
| Operating Income | (61K) | 542K | (1.4M) | (599K) |
| Net Income | (79K) | 526K | (1.4M) | (219K) |
| Diluted EPS | $-0.05 | N/A | $-0.81 | $-0.12 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 9.4M | 15.2M | 18.5M | 24.0M |
| Gross Profit | 2.5M | 6.0M | 7.6M | 10.7M |
| Net Income | (12.2M) | (5.9M) | (4.3M) | (363K) |
| Diluted EPS | $-10.73 | $-4.51 | $-2.93 | $-0.23 |